1. Home
  2. FRME vs EVO Comparison

FRME vs EVO Comparison

Compare FRME & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo First Merchants Corporation

FRME

First Merchants Corporation

HOLD

Current Price

$37.54

Market Cap

2.2B

Sector

Finance

ML Signal

HOLD

Logo Evotec SE

EVO

Evotec SE

HOLD

Current Price

$3.10

Market Cap

1.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FRME
EVO
Founded
1893
1993
Country
United States
Germany
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.2B
1.1B
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
FRME
EVO
Price
$37.54
$3.10
Analyst Decision
Buy
Strong Buy
Analyst Count
4
1
Target Price
$47.33
$7.00
AVG Volume (30 Days)
282.9K
254.9K
Earning Date
01-29-2026
11-05-2025
Dividend Yield
3.82%
N/A
EPS Growth
32.99
N/A
EPS
4.00
N/A
Revenue
$649,589,000.00
$887,396,457.00
Revenue This Year
$13.81
N/A
Revenue Next Year
$14.43
$8.52
P/E Ratio
$9.41
N/A
Revenue Growth
9.53
N/A
52 Week Low
$33.13
$2.84
52 Week High
$45.62
$4.80

Technical Indicators

Market Signals
Indicator
FRME
EVO
Relative Strength Index (RSI) 45.80 48.75
Support Level $38.06 $3.03
Resistance Level $38.96 $3.18
Average True Range (ATR) 0.61 0.08
MACD -0.17 0.03
Stochastic Oscillator 6.41 72.58

Price Performance

Historical Comparison
FRME
EVO

About FRME First Merchants Corporation

First Merchants Corp, through its subsidiaries, provides its customers with financial services delivered locally by bankers. It offers personal banking, business banking, real estate mortgage lending, cash management services, brokerage, wealth management, and insurance. The company reports in only one segment which is community banking.

About EVO Evotec SE

Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.

Share on Social Networks: